Pediatric Multiple Sclerosis Management and Therapeutics

Pediatric‐onset multiple sclerosis (MS) presents a distinct clinical challenge, characterised by a high relapse rate, more pronounced inflammatory activity and evolving considerations for central nervous system maturation. Early and accurate diagnosis, guided by consensus criteria adapted for paediatric populations, is crucial for differentiating MS from acute demyelinating syndromes and mimickers. Advanced imaging techniques, including MRI lesion quantification, support diagnosis and monitoring. Management strategies now favour prompt initiation of disease‐modifying therapies (DMTs) to mitigate long‐term disability, cognitive impairment and neurodevelopmental impact. Treatment paradigms range from moderate efficacy therapies (METs) to highly effective therapies (HETs), with decisions tailored to disease severity, safety profiles and patient lifestyle. Escalation versus induction approaches require careful weighing of short‐ and long‐term safety, developmental pharmacokinetics and ethical considerations in trial design. Multidisciplinary care, encompassing neurology, rehabilitation, neuropsychology and patient education, underpins optimisation of outcomes, emphasising adherence, monitoring of treatment‐related adverse events and reintegration into schooling and social activities. Emerging therapies and biomarkers continue to refine therapeutic windows, with the ultimate goal of achieving no evidence of disease activity (NEDA) while preserving neurocognitive function and quality of life.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pediatric Multiple Sclerosis Management and Therapeutics publication trend

The graph below shows the total number of articles in pediatric multiple sclerosis management and therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Disease‐Modifying Therapy (DMT): A pharmacological agent intended to alter the course of MS by reducing relapse frequency and slowing disability progression.

Moderate Efficacy Therapy (MET): DMTs with established safety profiles but lower potency in preventing relapses and radiologic activity.

Highly Effective Therapy (HET): DMTs demonstrating superior reduction in relapse rates and MRI lesion accrual, often with increased safety monitoring requirements.

Annualised Relapse Rate (ARR): The average number of clinical relapses per patient per year, a key efficacy endpoint in MS trials.

Expanded Disability Status Scale (EDSS): A standardised scale for quantifying disability in MS, ranging from 0 (normal) to 10 (death due to MS).

Magnetic Resonance Imaging (MRI): A non‐invasive imaging modality essential for detecting demyelinating lesions and monitoring disease activity.

No Evidence of Disease Activity (NEDA): A composite measure indicating absence of clinical relapses, disability progression and new MRI lesions during follow‐up.

References

1. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis. JAMA Neurology (2024).
2. Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod. Journal of Neurology (2024).
3. Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Neurology Neuroimmunology & Neuroinflammation (2021).